| 000 | 01700 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514004143.0 | ||
| 264 | 0 | _c20010906 | |
| 008 | 200109s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/hc2901.093504 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGilchrist, I C | |
| 245 | 0 | 0 |
_aPharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. _h[electronic resource] |
| 260 |
_bCirculation _cJul 2001 |
||
| 300 |
_a406-11 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides _xpharmacokinetics |
| 650 | 0 | 4 |
_aPlatelet Aggregation _xdrug effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aO'Shea, J C | |
| 700 | 1 | _aKosoglou, T | |
| 700 | 1 | _aJennings, L K | |
| 700 | 1 | _aLorenz, T J | |
| 700 | 1 | _aKitt, M M | |
| 700 | 1 | _aKleiman, N S | |
| 700 | 1 | _aTalley, D | |
| 700 | 1 | _aAguirre, F | |
| 700 | 1 | _aDavidson, C | |
| 700 | 1 | _aRunyon, J | |
| 700 | 1 | _aTcheng, J E | |
| 773 | 0 |
_tCirculation _gvol. 104 _gno. 4 _gp. 406-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/hc2901.093504 _zAvailable from publisher's website |
| 999 |
_c11395893 _d11395893 |
||